The authors make no claims of the accuracy of the information contained
herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this document shall be liable for any special,
consequential, or exemplary damages resulting in whole or part from any
user's use of or reliance upon this material. PLEASE
READ THE DISCLAIMER CAREFULLY BEFORE
ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE
TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.
Standard Dilutions [Amount of drug]
[Infusion volume] [Infusion rate]
[0 to 10 mg] [50 ml] [As directed]
HALDOL INJECTION IS NOT APPROVED FOR INTRAVENOUS ADMINISTRATION.
[See WARNING below]
Stability / Miscellaneous
EXP: 7 DAYS (RT) Label: Do not Refrigerate. Protect from light.
Oral to IV conversion (approximate): oral dose x 0.625
= daily IV dose.
Package Insert - WARNING:
Cases of sudden death, QT-prolongation, and Torsades de Pointes
have been reported in patients receiving HALDOL. Higher than
recommended doses of any formulation and intravenous
administration of HALDOL appear to be associated with a higher
risk of QT-prolongation and Torsades de Pointes. Although cases
have been reported even in the absence of predisposing factors,
particular caution is advised in treating patients with other
QT-prolonging conditions (including electrolyte imbalance
[particularly hypokalemia and hypomagnesemia], drugs known to
prolong QT, underlying cardiac abnormalities, hypothyroidism,
and familial long QT-syndrome). HALDOL INJECTION IS NOT
APPROVED FOR INTRAVENOUS ADMINISTRATION. If HALDOL is
administered intravenously, the ECG should be monitored for QT
prolongation and arrhythmias.
DOSAGE AND ADMINISTRATION
There is considerable variation from patient to patient
in the amount of medication required for treatment. As
with all drugs used to treat schizophrenia, dosage
should be individualized according to the needs and
response of each patient. Dosage adjustments, either
upward or downward, should be carried out as rapidly as
practicable to achieve optimum therapeutic control.
To determine the initial dosage, consideration should be
given to the patient's age, severity of illness,
previous response to other antipsychotic drugs, and any
concomitant medication or disease state. Debilitated or
geriatric patients, as well as those with a history of
adverse reactions to antipsychotic drugs, may require
less HALDOL (haloperidol). The optimal response in such
patients is usually obtained with more gradual dosage
adjustments and at lower dosage levels.
Parenteral medication, administered intramuscularly in
doses of 2 to 5 mg, is utilized for prompt control of
the acutely agitated schizophrenic patient with
moderately severe to very severe symptoms. Depending on
the response of the patient, subsequent doses may be
given, administered as often as every hour, although 4
to 8 hour intervals may be satisfactory.
Controlled trials to establish the safety and
effectiveness of intramuscular administration in
children have not been conducted.
Parenteral drug products should be inspected visually
for particulate matter and discoloration prior to
administration, whenever solution and container permit.
Patients over 65 years old generally should not receive >2 mg/24 hours.
If higher doses are given, (ECG) monitoring is recommended. Usual
starting doses are 0.25 - 0.5 mg given no more than twice a day.
An oral form should supplant the injectable as soon as
practicable. In the absence of bioavailability studies
establishing bioequivalence between these two dosage
forms the following guidelines for dosage are suggested.
For an initial approximation of the total daily dose
required, the parenteral dose administered in the
preceding 24 hours may be used. Since this dose is only
an initial estimate, it is recommended that careful
monitoring of clinical signs and symptoms, including
clinical efficacy, sedation, and adverse effects, be
carried out periodically for the first several days
following the initiation of switchover. In this way,
dosage adjustments, either upward or downward, can be
quickly accomplished. Depending on the patient's
clinical status, the first oral dose should be given
within 12–24 hours following the last parenteral dose.
Source: [package insert]
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical
judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER
BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU
AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.